Introduction
Methods
Patients
Magnetoencephalography
Peritumor, global, and non-tumor oscillatory activity
Tissue micro array and immunohistochemistry
Possible confounders of oscillatory brain activity and progression free survival
Statistical analyses
Results
Patient characteristics
M/F | Age | WHO 2007 diagnosis | IDH1 status | Tumor location | AED use | Tumor volume (cm3) | EOR (%) | Treatment after resection until progression | KPS | PFS or last follow-up (weeks) | OBA (z-score) | NLGN3 expression |
---|---|---|---|---|---|---|---|---|---|---|---|---|
M | 48 | OII | Mut | R-FrT | VPA | 14.93 | 100 | – | 70 | 301 | − 1.85 | Low |
F | 26 | AIII | Mutb | L-T | VPA | 147.33 | 99 | Re-resectiona, RTH, TMZ | 90 |
224
| − 1.49 | Low |
F | 26 | AIII | WTb | R-Fr | VPA | 35.02 | 93 | RTH | 100 | 321 | − 1.46 | Low |
M | 41 | OAII | Mut | L-P | VPA | 35.95 | 94 | RTH | 90 | 292 | − 0.84 | Low |
M | 37 | OIII | Mutc | R-Fr | VPA | 44.74 | 100 | RTH, PCV | 100 | 219 | − 0.69 | High |
F | 53 | AII | NA | L-T | LEV | 94.65 | 98 | RTH | 100 |
265
| − 0.62 | NA |
M | 47 | AIII | WTb | R-P | – | 41.30 | 76 | RTH, TMZ | 100 |
54
| − 0.47 | Low |
F | 28 | OII | Mutb | LT | LEV | 61.51 | 97 | – | 100 |
66
| − 0.37 | Low |
M | 28 | AII | WT | L-Fr | LEV | 68.07 | 96 | – | 100 |
45
| − 0.26 | Low |
M | 43 | AII | Mut | L-T | VPA | 53.41 | 100 | – | 80 | 305 | − 0.24 | Low |
F | 37 | AII | Mut | L-T | CBZ | 107.14 | 100 | – | 100 |
65
| − 0.23 | Low |
M | 36 | OIII | WTc | L-Fr | LEV | 27.61 | 97 | RTH | 100 | 293 | − 0.15 | High |
M | 18 | AII | Mut | L-Fr | VPA | 36.46 | 92 | – | 100 |
251
| − 0.14 | Low |
M | 35 | OAII | Mutc | R-P | LEV | 52.85 | 100 | – | 100 |
29
| − 0.12 | Moderate |
M | 30 | AII | WT | R-T | PHT, LEV | 85.03 | 91 | – | 100 |
156
| 0.23 | Low |
M | 46 | GBM | WT | L-Fr | VPA | 123.05 | 99 | RTH, TMZ | 90 |
39
| 0.31 | High |
M | 27 | AII | Mut | L-P | VPA | 48.54 | 92 | – | 90 |
93
| 0.33 | Low |
M | 37 | GBM | NA | L-Fr | LEV | 56.44 | 100 | RTH, TMZ | 100 |
87
| 0.46 | NA |
F | 48 | AII | Mut | R-T | VPA | 72.42 | 100 | – | 100 |
106
| 0.50 | Moderate |
M | 52 | OII | Mutc | L-T | – | 53.22 | 97 | – | 100 |
250
| 0.57 | Moderate |
M | 58 | OIII | Mutc | L-Fr | LEV | 35.20 | 100 | RTH, PCV | 90 | 200 | 0.74 | Moderate |
M | 30 | AII | NA | L-Fr | PHT | 35.27 | 100 | – | 90 |
54
| 1.69 | NA |
M | 46 | OAII | Mut | R-T | VPA | 76.58 | 88 | – | 100 |
164
| 1.72 | Moderate |
M | 50 | AII | WT | L-T | – | 47.68 | 95 | – | 80 |
8
| 2.38 | Moderate |
Expression of NLGN3 is associated with oscillatory brain activity
Oscillatory brain activity predicts progression free survival
Confounding factors do not influence the predictive value of global oscillatory activity for PFS
Confounders | Global oscillatory activity | Confounder | ||||
---|---|---|---|---|---|---|
HR | CI | P-value | HR | CI | P-value | |
Age (≤ 40) | 2.40 | 1.33–4.36 | 0.004** | 2.20 | 0.78–3.22 | 0.138 |
Age (years continuous) | 2.33 | 1.31–4.13 | 0.004** | 0.97 | 0.93–1.02 | 0.210 |
Gender | 2.49 | 1.35–4.61 | 0.004** | 0.44 | 0.13–1.47 | 0.183 |
KPS (≤ 80) | 2.04 | 1.17–3.58 | 0.013* | 0.49 | 0.06–3.88 | 0.497 |
WHO grade | 2.05 | 1.17–3.59 | 0.013* | 1.23 | 0.39–3.93 | 0.723 |
Histology | 2.37 | 1.32–4.25 | 0.004** | 2.23 | 1.03–4.82 | 0.041* |
IDH1 mutation status (N = 18) | 2.13 | 1.14–3.97 | 0.018* | 2.10 | 0.66–6.69 | 0.209 |
IDH1 mutation status combined with 1p/19q codeletion (N = 18) | 2.88 | 1.14–7.28 | 0.025* | 2.33 | 0.99–5.51 | 0.054 |
Adjuvant treatment | 2.09 | 1.17–3.74 | 0.013* | 1.02 | 0.52–2.00 | 0.958 |
Tumor volume (cm3) | 2.29 | 1.33–3.93 | 0.003** | 1.02 | 1.00–1.04 | 0.019* |
Tumor diameter (< 6 cm) | 2.02 | 1.16–3.51 | 0.013* | 0.68 | 0.26–1.82 | 0.445 |
Non-eloquent area | 2.28 | 1.28–4.06 | 0.005** | 0.52 | 0.17–1.60 | 0.256 |
Head size | 2.23 | 1.24–4.01 | 0.007** | 1.16 | 0.69–1.93 | 0.580 |